Ignite Creation Date:
2024-05-06 @ 7:13 AM
Last Modification Date:
2024-10-26 @ 11:46 AM
Study NCT ID:
NCT02497157
Status:
COMPLETED
Last Update Posted:
2020-06-17
First Post:
2015-06-25
Brief Title:
Bevacizumab Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
Sponsor:
Translational Research Center for Medical Innovation Kobe Hyogo Japan
Organization:
Translational Research Center for Medical Innovation Kobe Hyogo Japan
Study Overview
Official Title:
Phase II Trial of FOLFOXIRI Bevacizumab in Patients With Untreated Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BeTRI
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of fluorouracil 5-FU levofolinate calcium l-LV oxaliplatin L-OHP and irinotecan hydrochloride hydrate CPT-11 FOLFOXIRI plus bevacizumab in untreated metastatic colorectal cancer patients who harbor Uridine diphosphate UDP-glucuronosyl transferase 1A1 UGT1A1 11 16 or 128
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UMIN000017102 | OTHER | UMIN-CTR | None |